Epigenetics, Microbiome and Personalized Medicine: Focus on Kidney Disease

被引:2
|
作者
Gigliotti, Giuseppe [1 ]
Joshi, Rashmi [2 ]
Khalid, Anam [2 ]
Widmer, David [3 ]
Boccellino, Mariarosaria [4 ,5 ]
Viggiano, Davide [2 ]
机构
[1] Eboli Hosp, Dept Nephrol & Dialysis, I-84025 Eboli, Italy
[2] Univ Campania, Dept Translat Med Sci, I-81100 Naples, Italy
[3] Vidmar Daj Consulting, New York, NY 07093 USA
[4] Univ Campania Luigi Vanvitelli, Dept Expt Med, I-81100 Naples, Italy
[5] Link Univ, Dept Life Sci Hlth & Hlth Profess, I-00165 Rome, Italy
关键词
microbiome; IgAN; epigenome; DNA METHYLATION AGE; GUT MICROBIOTA; WEIGHT; NUMBER; MOUSE; SIZE;
D O I
10.3390/ijms25168592
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Personalized medicine, which involves modifying treatment strategies/drug dosages based on massive laboratory/imaging data, faces large statistical and study design problems. The authors believe that the use of continuous multidimensional data, such as those regarding gut microbiota, or binary multidimensional systems properly transformed into a continuous variable, such as the epigenetic clock, offer an advantageous scenario for the design of trials of personalized medicine. We will discuss examples focusing on kidney diseases, specifically on IgA nephropathy. While gut dysbiosis can provide a treatment strategy to restore the standard gut microbiota using probiotics, transforming epigenetic omics data into epigenetic clocks offers a promising tool for personalized acute and chronic kidney disease care. Epigenetic clocks involve a complex transformation of DNA methylome data into estimated biological age. These clocks can identify people at high risk of developing kidney problems even before symptoms appear. Some of the effects of both the epigenetic clock and microbiota on kidney diseases seem to be mediated by endothelial dysfunction. These "big data" (epigenetic clocks and microbiota) can help tailor treatment plans by pinpointing patients likely to experience rapid declines or those who might not need overly aggressive therapies.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Proteomics and personalized medicine: a focus on kidney disease
    Siwy, Justyna
    Mischak, Harald
    Zuerbig, Petra
    EXPERT REVIEW OF PROTEOMICS, 2019, 16 (09) : 773 - 782
  • [2] Personalized Medicine in Kidney Disease
    Gembillo, Guido
    Siligato, Rossella
    Santoro, Domenico
    JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (10):
  • [3] The Promise of Epigenetics in Personalized Medicine
    Weber, Wendell W.
    MOLECULAR INTERVENTIONS, 2010, 10 (06) : 363 - 370
  • [4] Integrating epigenetics into personalized medicine
    Worsham, M. J.
    Chen, K. M.
    Stephen, J. K.
    Datta, I.
    Divine, G.
    EUROPEAN JOURNAL OF CANCER, 2016, 54 : S44 - S44
  • [5] Panoramic on Epigenetics in Coronary Artery Disease and the Approach of Personalized Medicine
    Bergonzini, Marcello
    Loreni, Francesco
    Lio, Antonio
    Russo, Marco
    Saitto, Guglielmo
    Cammardella, Antonio
    Irace, Francesco
    Tramontin, Corrado
    Chello, Massimo
    Lusini, Mario
    Nenna, Antonio
    Ferrisi, Chiara
    Ranocchi, Federico
    Musumeci, Francesco
    BIOMEDICINES, 2023, 11 (10)
  • [6] The relevance of epigenetics and the epigenome for personalized medicine
    Bock, C.
    ONKOLOGIE, 2013, 36 : 281 - 281
  • [7] Epigenetics and the developmental origins of disease: the key to unlocking the door of personalized medicine
    Joss-Moore, Lisa A.
    Lane, Robert H.
    EPIGENOMICS, 2012, 4 (05) : 471 - 473
  • [8] The significance of microbiome in personalized medicine
    Behrouzi, Ava
    Nafari, Amir Hossein
    Siadat, Seyed Davar
    CLINICAL AND TRANSLATIONAL MEDICINE, 2019, 8
  • [9] Utilization of the microbiome in personalized medicine
    Ratiner, Karina
    Ciocan, Dragos
    Abdeen, Suhaib K.
    Elinav, Eran
    NATURE REVIEWS MICROBIOLOGY, 2024, 22 (05) : 291 - 308
  • [10] Microbiome at the Frontier of Personalized Medicine
    Kashyap, Purna C.
    Chia, Nicholas
    Nelson, Heidi
    Segal, Eran
    Elinav, Eran
    MAYO CLINIC PROCEEDINGS, 2017, 92 (12) : 1855 - 1864